This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: Jim Hollingshead New title: President and CEO, BVI Previous title: CEO, Insulet Ophthalmic device business BVI has named former Insulet CEO Jim Hollingshead as its next leader, the company said Monday. Hollingshead led Insulet, which sells the Omnipod insulin pump, for three years before resigning in 2025. Ashley McEvoy, the former head of Johnson & Johnson’s ...

Core Viewpoint - Ocumetics Technology Corp. has successfully closed a private placement offering, raising approximately $1,023,830 through the sale of 1,706,383 units, which will be utilized for clinical trials, research and development, and general corporate purposes [1][3][4]. Group 1: Offering Details - The first tranche of the brokered private placement generated gross proceeds of about $788,380, while a concurrent non-brokered private placement added approximately $235,450, totaling around $1,023,830 [1][3]. - Each unit was priced at $0.60 and consists of one common share and one warrant, allowing the purchase of an additional common share at $0.75 until December 30, 2028 [3]. - The company incurred $143,336.17 in commissions and fees related to the offerings, with part of this amount paid in units and additional warrants issued [5]. Group 2: Use of Proceeds - The gross proceeds from the offerings are earmarked for funding the corporation's first-in-human clinical trials, ongoing research and development, and general corporate purposes, although actual allocation may vary [4]. Group 3: Related Party Transactions - Key executives and directors of the corporation participated in the private placement, qualifying it as a "Related Party Transaction" under applicable regulations, with exemptions from minority shareholder approval requirements being utilized [7].